XLON
BVXP
Market cap120mUSD
Oct 07, Last price
1,750.00GBP
1D
1.45%
1Q
9.38%
Jan 2017
29.63%
IPO
194.12%
Name
Bioventix PLC
Chart & performance
P/E
12.06
P/S
6.97
EPS
1.45
Div yield, %
8.57%
Shrs. gr., 5y
0.27%
Rev. gr., 5y
4.92%
Revenues
13m
-3.61%
Net income
8m
-6.33%
CFO
7m
-15.73%
Dividend
Apr 09, 202670 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Key people
Non-Executive Chairman of the Board
P. Harrison
Chief Executive Officer, Director
T. Turner
Director · since 2012
Nick McCooke
Non-Executive Director · since 2014
Legal address
27-28 EASTCASTLE STREET
LONDON, LND W1W 8DH
GB
LONDON, LND W1W 8DH
GB
Headquarters
7 ROMANS BUSINESS PARK
EAST STREET
FARNHAM, SRY GU9 7SX
GB
EAST STREET
FARNHAM, SRY GU9 7SX
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||